Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Total Non-Current Liabilities (2018 - 2021)

Historic Total Non-Current Liabilities for Cue Biopharma (CUE) over the last 4 years, with Q4 2021 value amounting to $17.9 million.

  • Cue Biopharma's Total Non-Current Liabilities fell 415.25% to $17.9 million in Q4 2021 from the same period last year, while for Dec 2021 it was $17.9 million, marking a year-over-year decrease of 415.25%. This contributed to the annual value of $17.9 million for FY2021, which is 415.25% down from last year.
  • Per Cue Biopharma's latest filing, its Total Non-Current Liabilities stood at $17.9 million for Q4 2021, which was down 415.25% from $16.7 million recorded in Q2 2021.
  • Cue Biopharma's Total Non-Current Liabilities' 5-year high stood at $19.0 million during Q2 2020, with a 5-year trough of $3.0 million in Q2 2018.
  • For the 4-year period, Cue Biopharma's Total Non-Current Liabilities averaged around $13.6 million, with its median value being $15.3 million (2019).
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first soared by 40809.99% in 2019, then tumbled by 2085.05% in 2020.
  • Over the past 4 years, Cue Biopharma's Total Non-Current Liabilities (Quarter) stood at $6.2 million in 2018, then surged by 109.16% to $13.0 million in 2019, then skyrocketed by 43.69% to $18.7 million in 2020, then fell by 4.15% to $17.9 million in 2021.
  • Its Total Non-Current Liabilities was $17.9 million in Q4 2021, compared to $16.7 million in Q2 2021 and $17.7 million in Q1 2021.